446 related articles for article (PubMed ID: 33965062)
1. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus seasonality, transmission zones, and implications for seasonal prevention strategy in China: a systematic analysis.
Guo L; Deng S; Sun S; Wang X; Li Y
Lancet Glob Health; 2024 Jun; 12(6):e1005-e1016. PubMed ID: 38670132
[TBL] [Abstract][Full Text] [Related]
3. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
[TBL] [Abstract][Full Text] [Related]
4. Modeling the optimal seasonal monoclonal antibody administration strategy for respiratory syncytial virus (RSV) prevention based on age-season specific hospitalization rate of RSV in Suzhou, China, 2016-2022.
Ren S; Chen Q; Zhang Y; Yi L; Qian C; Lu Y; Shen J; Liu X; Jiang M; Wang B; Song J; Shao X; Zhang T; Tian J; Zhao G
Vaccine; 2024 Jan; 42(2):352-361. PubMed ID: 38057209
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus seasonality and its implications on prevention strategies.
Janet S; Broad J; Snape MD
Hum Vaccin Immunother; 2018 Jan; 14(1):234-244. PubMed ID: 29194014
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
[TBL] [Abstract][Full Text] [Related]
7. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
[TBL] [Abstract][Full Text] [Related]
8. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
Li Y; Wang X; Blau DM; Caballero MT; Feikin DR; Gill CJ; Madhi SA; Omer SB; Simões EAF; Campbell H; Pariente AB; Bardach D; Bassat Q; Casalegno JS; Chakhunashvili G; Crawford N; Danilenko D; Do LAH; Echavarria M; Gentile A; Gordon A; Heikkinen T; Huang QS; Jullien S; Krishnan A; Lopez EL; Markić J; Mira-Iglesias A; Moore HC; Moyes J; Mwananyanda L; Nokes DJ; Noordeen F; Obodai E; Palani N; Romero C; Salimi V; Satav A; Seo E; Shchomak Z; Singleton R; Stolyarov K; Stoszek SK; von Gottberg A; Wurzel D; Yoshida LM; Yung CF; Zar HJ; ; Nair H;
Lancet; 2022 May; 399(10340):2047-2064. PubMed ID: 35598608
[TBL] [Abstract][Full Text] [Related]
9. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
Cong B; Koç U; Bandeira T; Bassat Q; Bont L; Chakhunashvili G; Cohen C; Desnoyers C; Hammitt LL; Heikkinen T; Huang QS; Markić J; Mira-Iglesias A; Moyes J; Nokes DJ; Ploin D; ; Seo E; Singleton R; Wolter N; Fu Yung C; Zar HJ; Feikin DR; Sparrow EG; ; Nair H; Li Y;
Lancet Infect Dis; 2024 Apr; 24(4):361-374. PubMed ID: 38141633
[TBL] [Abstract][Full Text] [Related]
10. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study.
Li Y; Johnson EK; Shi T; Campbell H; Chaves SS; Commaille-Chapus C; Dighero I; James SL; Mahé C; Ooi Y; Paget J; van Pomeren T; Viboud C; Nair H
Lancet Respir Med; 2021 Feb; 9(2):175-185. PubMed ID: 32971018
[TBL] [Abstract][Full Text] [Related]
11. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
[TBL] [Abstract][Full Text] [Related]
12. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
[TBL] [Abstract][Full Text] [Related]
14. Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.
; Le TG; Ngo L; Mehta S; Do VD; Thach TQ; Vu XD; Nguyen DT; Cohen A
Res Rep Health Eff Inst; 2012 Jun; (169):5-72; discussion 73-83. PubMed ID: 22849236
[TBL] [Abstract][Full Text] [Related]
15. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.
Shi T; McAllister DA; O'Brien KL; Simoes EAF; Madhi SA; Gessner BD; Polack FP; Balsells E; Acacio S; Aguayo C; Alassani I; Ali A; Antonio M; Awasthi S; Awori JO; Azziz-Baumgartner E; Baggett HC; Baillie VL; Balmaseda A; Barahona A; Basnet S; Bassat Q; Basualdo W; Bigogo G; Bont L; Breiman RF; Brooks WA; Broor S; Bruce N; Bruden D; Buchy P; Campbell S; Carosone-Link P; Chadha M; Chipeta J; Chou M; Clara W; Cohen C; de Cuellar E; Dang DA; Dash-Yandag B; Deloria-Knoll M; Dherani M; Eap T; Ebruke BE; Echavarria M; de Freitas Lázaro Emediato CC; Fasce RA; Feikin DR; Feng L; Gentile A; Gordon A; Goswami D; Goyet S; Groome M; Halasa N; Hirve S; Homaira N; Howie SRC; Jara J; Jroundi I; Kartasasmita CB; Khuri-Bulos N; Kotloff KL; Krishnan A; Libster R; Lopez O; Lucero MG; Lucion F; Lupisan SP; Marcone DN; McCracken JP; Mejia M; Moisi JC; Montgomery JM; Moore DP; Moraleda C; Moyes J; Munywoki P; Mutyara K; Nicol MP; Nokes DJ; Nymadawa P; da Costa Oliveira MT; Oshitani H; Pandey N; Paranhos-Baccalà G; Phillips LN; Picot VS; Rahman M; Rakoto-Andrianarivelo M; Rasmussen ZA; Rath BA; Robinson A; Romero C; Russomando G; Salimi V; Sawatwong P; Scheltema N; Schweiger B; Scott JAG; Seidenberg P; Shen K; Singleton R; Sotomayor V; Strand TA; Sutanto A; Sylla M; Tapia MD; Thamthitiwat S; Thomas ED; Tokarz R; Turner C; Venter M; Waicharoen S; Wang J; Watthanaworawit W; Yoshida LM; Yu H; Zar HJ; Campbell H; Nair H;
Lancet; 2017 Sep; 390(10098):946-958. PubMed ID: 28689664
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
[TBL] [Abstract][Full Text] [Related]
17. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
[TBL] [Abstract][Full Text] [Related]
18. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
[TBL] [Abstract][Full Text] [Related]
19. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
Atwell JE; Lutz CS; Sparrow EG; Feikin DR
Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
Getaneh AM; Li X; Mao Z; Johannesen CK; Barbieri E; van Summeren J; Wang X; Tong S; Baraldi E; Phijffer E; Rizzo C; van Wijhe M; Heikkinen T; Bont L; Willem L; Jit M; Beutels P; Bilcke J;
Vaccine; 2023 Feb; 41(9):1623-1631. PubMed ID: 36737318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
